Management of hypertension with fixed-dose triple-combination treatments

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 5, 2013, Pages 246-259

  Epstein, Benjamin J ^a   Shah, Niren K ^b   Borja Hart, Nancy L ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b East Coast Institute for Research   (United States)

Author keywords

aliskiren; amlodipine; antihypertensive agents; drug combinations; fixed dose triple combination therapy; hydrochlorothiazide; hypertension; olmesartan; valsartan

Indexed keywords

ALISKIREN PLUS AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN;

BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; JOINT SWELLING; MUSCLE SPASM; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ALISKIREN; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FIXED-DOSE TRIPLE-COMBINATION THERAPY; HYDROCHLOROTHIAZIDE; HYPERTENSION; OLMESARTAN; VALSARTAN;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84886897748     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944713498638     Document Type: Article

References (88)

1. Bailey J. Wan J. Tang J. Ghani M. Cushman W. (2010) Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 25: 495–503.
2. Bangalore S. Kamalakkannan G. Parkar S. Messerli F. (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120: 713–719.
3. Barreras A. Gurk-Turner C. (2003) Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent ) 16: 123–126.
4. Birkenhager W. (1990) Diuretics and blood pressure reduction: physiologic aspects. J Hypertens Suppl 8: S3–S7.
5. Bramley T. Gerbino P. Nightengale B. Frech-Tamas F. (2006) Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 12: 239–245.
6. Brixner D. Jackson K. Sheng X. Nelson R. Keskinaslan A. (2008) Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin 24: 2597–2607.
7. Burnier M. (2001) Angiotensin II type 1 receptor blockers. Circulation 103: 904–912.
8. Calhoun D. Crikelair N. Yen J. Glazer R. (2009 a) Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate / severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther 26: 1012–1023.
9. Calhoun D. Lacourciere Y. Chiang Y. Glazer R. (2009 b) Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. A randomized clinical trial. Hypertension 54: 32–39.
10. Cherry S. Benner J. Hussein M. Tang S. Nichol M. (2009) The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 12: 489–497.
11. Chobanian A. Bakris G. Black H. Cushman W. Green L. Izzo J. Jr et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252.
12. Chrysant S. (2008) Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 28: 713–734.
13. Chrysant S. (2012) Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in blacks and non-blacks with hypertension: a subgroup analysis of the TRINITY study. Am J Cardiovasc Drugs 12: 233–243.
14. Chrysant S. Izzo J. Jr Kereiakes D. Littlejohn T. III Oparil S. Melino M. et al. (2012) Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens 6: 132–141.
15. Cushman W. Ford C. Cutler J. Margolis K. Davis B. Grimm R. et al. (2002) Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393–404.
16. Daiichi Sankyo Inc. (2012 a) Benicar prescribing information [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.
17. Daiichi Sankyo Inc. (2012 b) Tribenzor prescribing information [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.
18. Dickson M. Plauschinat C. (2008) Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 18: 204–209.
19. Dragomir A. Cote R. Roy L. Blais L. Lalonde L. Berard A. et al. (2010) Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 48: 418–425.
20. Egan B. Zhao Y. Axon R. (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303: 2043–2050.
21. Elijovich F. Laffer C. (2009) A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 3: 231–240.
22. Epstein B. (2010) Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opin Pharmacother 11: 2011–2026.
23. FDA (2011) Guidance for Industry. Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims. Silver Spring, MD: US Food and Drug Administration. [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075072.pdf;accessed 5 December 2011]
24. FDA (2012) FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna). Silver Spring, MD: US Food and Drug Administration. [http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm;accessed 27 April 2012]
25. Feldman R. Zou G. Vandervoort M. Wong C. Nelson S. Feagan B. (2009) A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53: 646–653.
26. Ferdinand K. Weitzman R. Israel M. Lee J. Purkayastha D. Jaimes E. (2011) Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens 5: 102–113.
27. Flack J. Sica D. Bakris G. Brown A. Ferdinand K. Grimm R. Jr et al. (2010) Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56: 780–800.
28. Fogari R. Zoppi A. (2010) New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag 6: 869–882.
29. Fung V. Huang J. Brand R. Newhouse J. Hsu J. (2007) Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther 29: 972–984.
30. Go A. Mozaffarian D. Roger V. Benjamin E. Berry J. Borden W. et al. (2013) Heart disease and stroke statistics – 2013 update – a report from the American Heart Association. Circulation 127: 143–152.
31. Gradman A. (2010) Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 12: 869–878.
32. Gradman A. Basile J. Carter B. Bakris G. (2010) Combination therapy in hypertension. J Am Soc Hypertens 4: 42–50.
33. Gradman A. Parise H. Lafeuille M. Falvey H. Lefebvre P. Duh M. (2011) Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: a matched cohort study [abstract]. J Clin Hypertens 13(Suppl. 1): A128.
34. Gradman A. Parise H. Lefebvre P. Falvey H. Lafeuille M. Duh M. (2013) Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 61: 309–318.
35. Gupta A. Arshad S. Poulter N. (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55: 399–407.
36. Hansson L. Zanchetti A. Carruthers S. Dahlof B. Elmfeldt D. Julius S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762.
37. Heidenreich P. Trogdon J. Khavjou O. Butler J. Dracup K. Ezekowitz M. et al. (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123: 933–944.
38. Heisler M. Hogan M. Hofer T. Schmittdiel J. Pladevall M. Kerr E. (2008) When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation 117: 2884–2892.
39. Hess G. Hill J. Lau H. Dastani H. Chaudhari P. (2008) Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T 33: 652–666.
40. Hjemdahl P. (1984) Sympatho-adrenal mechanisms and the antihypertensive response to thiazide diuretics. Acta Pharmacol Toxicol (Copenh) 54(Suppl. 1): 43–46.
41. Ho P. Magid D. Shetterly S. Olson K. Peterson P. Masoudi F. et al. (2008) Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 168: 271–276.
42. Hughes A. (2004) How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 5: 155–160.
43. Hyman D. Pavlik V. (2000) Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 160: 2281–2286.
44. Izzo J. Jr Chrysant S. Kereiakes D. Littlejohn T. III Oparil S. Melino M. et al. (2011) 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich) 13: 873–880.
45. Jamerson K. (2003) The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). J Clin Hypertens (Greenwich) 5: 29–35.
46. Jamerson K. Bakris G. Dahlof B. Pitt B. Velazquez E. Gupte J. et al. (2007) Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 16: 80–86.
47. Julius S. Kjeldsen S. Weber M. Brunner H. Ekman S. Hansson L. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031.
48. Kereiakes D. Chrysant S. Izzo J. Jr Littlejohn T. Oparil S. Melino M. et al. (2012) Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for hypertension. J Clin Hypertens 14: 149–157.
49. Klahr S. Levey A. Beck G. Caggiula A. Hunsicker L. Kusek J. et al. (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877–884.
50. Lacourciere Y. Crikelair N. Glazer R. Yen J. Calhoun D. (2011) 24-hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens 25: 615–622.
51. Lacourciere Y. Taddei S. Konis G. Fang H. Severin T. Zhang J. (2012) Clinic and ambulatory blood pressure-lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens 30: 2047–2055.
52. Lannett Company Inc. (2007) Hydrochlorothiazide prescribing information [package insert]. Philadelphia, PA: Lannett Company, Inc.
53. Lewington S. Clarke R. Qizilbash N. Peto R. Collins R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913.
54. Lithell H. Hansson L. Skoog I. Elmfeldt D. Hofman A. Olofsson B. et al. (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886.
55. Lynch W. Markosyan K. Melkonian A. Pesa J. Kleinman N. (2009) Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care 15: 871–880.
56. Mancia G. Laurent S. Agabiti-Rosei E. Ambrosioni E. Burnier M. Caulfield M. et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158.
57. Murray A. Koenig W. Garcia-Puig J. Patel S. Uddin A. Zhang J. (2012) Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. J Clin Hypertens (Greenwich) 14: 821–827.
58. Nesbitt S. (2010) Overcoming therapeutic inertia in patients with hypertension. Postgrad Med 122: 118–124.
59. NICE (2011) Hypertension: The Clinical Management of Primary Hypertension in Adults. Clinical Guideline 127. London: National Institute for Health and Clinical Excellence. [http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf; accessed 10 October 2011]
60. Noll G. Luscher T. (1998) Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology 89(Suppl. 1): 10–15.
61. Novartis Pharmaceuticals Corporation (2012 a) Amturnide prescribing information [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
62. Novartis Pharmaceuticals Corporation (2012 b) Diovan prescribing information [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
63. Novartis Pharmaceuticals Corporation (2012 c) Exforge HCT prescribing information [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
64. Novartis Pharmaceuticals Corporation (2012 d) Tekturna prescribing information [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
65. Ofili E. (2006) Dispelling the myth of “aggressive” antihypertensive therapy. J Clin Hypertens (Greenwich) 8: 4–11.
66. Okonofua E. Simpson K. Jesri A. Rehman S. Durkalski V. Egan B. (2006) Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47: 345–351.
67. Oparil S. Melino M. Lee J. Fernandez V. Heyrman R. (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 32: 1252–1269.
68. Oparil S. Weber M. (2009) Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 121: 25–39.
69. Panjabi S. Lacey M. Bancroft T. Cao F. (2013) Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 7: 46–60.
70. Pepine C. Handberg E. Cooper-De Hoff R. Marks R. Kowey P. Messerli F. et al. (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290: 2805–2816.
71. Pfizer Labs (2011) Norvasc prescribing information [package insert]. New York, NY: Pfizer Labs.
72. Pittman D. Tao Z. Chen W. Stettin G. (2010) Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 16: 568–576.
73. Richard S. (2005) Vascular effects of calcium channel antagonists: new evidence. Drugs 65(Suppl. 2): 1–10.
74. Rose A. Shimada S. Rothendler J. Reisman J. Glassman P. Berlowitz D. et al. (2008) The accuracy of clinician perceptions of “usual” blood pressure control. J Gen Intern Med 23: 180–183.
75. Rosendorff C. Black H. Cannon C. Gersh B. Gore J. Izzo J. Jr et al. (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761–2788.
76. Saseen J. MacLaughlin E. (2011) Hypertension. In: Ed. DiPiro J. Talbert R. Yee G. Matzke G. Wells B. Posey L. (eds), Pharmacotherapy: A Pathophysiologic Approach. Columbus, OH: McGraw-Hill.
77. Sherrill B. Halpern M. Khan S. Zhang J. Panjabi S. (2011) Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 13: 898–909.
78. Sica D. (2002) Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62: 443–462.
79. Sica D. (2004) Thiazide-type diuretics: ongoing considerations on mechanism of action. J Clin Hypertens (Greenwich) 6: 661–664.
80. Staessen J. Li Y. Thijs L. Wang J. (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28: 385–407.
81. Staessen J. Thijs L. Fagard R. Celis H. Birkenhager W. Bulpitt C. et al. (2004) Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22: 847–857.
82. Turnbull F. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535.
83. Vawter L. Tong X. Gemilyan M. Yoon P. (2008) Barriers to antihypertensive medication adherence among adults – United States, 2005. J Clin Hypertens (Greenwich) 10: 922–929.
84. Wald D. Law M. Morris J. Bestwick J. Wald N. (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122: 290–300.
85. Whitworth J. (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983–1992.
86. Wright J. Jr Bakris G. Greene T. Agodoa L. Appel L. Charleston J. et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421–2431.
87. Yang W. Chang J. Kahler K. Fellers T. Orloff J. Wu E. et al. (2010) Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 26: 2065–2076.
88. Zeng F. Patel B. Andrews L. Frech-Tamas F. Rudolph A. (2010) Adherence and persistence of single-pill ARB / CCB combination therapy compared to multiple-pill ARB / CCB regimens. Curr Med Res Opin 26: 2877–2887.